Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. We all know that MDS is a cancer of the ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS). The study aimed to develop the TPMQ for clinicians (mTPMQ), ...

Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS. Receiving early red blood cell transfusion for low-risk ...

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myelodysplastic syndrome treatment market was valued at US$ 2,324.8 million in 2018, and is expected to exhibit a CAGR of ...

(WASHINGTON – August 6, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results ...

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation. In myelodysplastic ...